User:Mr. Ibrahem/Prasugrel
Clinical data | |
---|---|
Trade names | Effient, Efient |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609027 |
License data | |
Pregnancy category |
|
Platelet inhibitor (P2Y12)[1] | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ≥79% |
Protein binding | Active metabolite: ~98% |
Elimination half-life | ~7 h (range 2 h to 15 h) |
Excretion | Urine (~68% inactive metabolites); feces (27% inactive metabolites) |
Identifiers | |
| |
Chemical and physical data | |
JSmol) | |
| |
| |
(what is this?) (verify) |
Prasugrel, sold under the brand name Effient and Efient, is a medication used to prevent blood clots in people with acute coronary syndrome (ACS) who getting percutaneous coronary intervention (PCI).[2] It is used together with aspirin.[2] It is taken by mouth.[2]
Common side effects include bleeding.platelet inhibitor of the P2Y12 platelet adenosine diphosphate (ADP)-receptor inhibitor type.[1]
Prasugrel was approved for use in Europe and the United States in 2009.
References
- ^ a b c d e "DailyMed - PRASUGREL- prasugrel hydrochloride tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 30 October 2021. Retrieved 29 October 2021.
- ^ a b c d e "Efient". Archived from the original on 26 February 2021. Retrieved 29 October 2021.
- ^ "Prasugrel Monograph for Professionals". Drugs.com. Archived from the original on 27 February 2021. Retrieved 29 October 2021.
- ^ ISBN 978-0857114105.
- ^ "Prasugrel Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 April 2021. Retrieved 29 October 2021.
- ISSN 2589-790X.